TY - JOUR
T1 - Percutaneous mitral valve repair :
T2 - Outcome improvement with operator experience and a second-generation device
AU - Freixa, X.
AU - Estevez-Loureiro, Rodrigo
AU - Carrasco-Chinchilla, Fernando
AU - Millán, X.
AU - Amat-Santos, Ignacio J
AU - Regueiro, Ander
AU - Nombela-Franco, L.
AU - Pascual, I.
AU - Cid-Álvarez, Belén
AU - López-Mínguez, J.R.
AU - Hernández-Antolín, R.A.
AU - Cruz-González, Ignacio
AU - Andraka, L.
AU - Goicolea, J.
AU - Ruíz-Quevedo, V.
AU - Díez, J.L.
AU - Berenguer, A.
AU - Baz, J.A.
AU - Pan, M.
AU - Benito-González, T.
AU - Alonso Briales, J.H.
AU - Li, Chi Hion
AU - Sanchis, L.
AU - Serrador, A.
AU - Jiménez-Quevedo, P.
AU - Avanzas, Pablo
AU - Salido, L.
AU - Fernández-Vázquez, Felipe
AU - Hernández-García, J.M.
AU - Arzamendi, Dabit
PY - 2021
Y1 - 2021
N2 - Background and aim: Recent randomized data comparing percutaneous mitral valve repair (PMVR) versus optimal medical treatment in patients with functional MR (FMR) seemed to highlight the importance of the learning curve not only for procedural outcomes but also for patient selection. The aim of the study was to compare a contemporary series of patients undergoing PMVR using a second-generation Mitraclip device (Mitraclip NT) with previous cohorts treated with a first-generation system. Methods: This multicenter study collected individual data from 18 centers between 2012 and 2017. The cohort was divided into three groups according to the use of the first-generation Mitraclip during the first (control-1) or second half (control-2) or the Mitraclip NT sys-tem. Results: A total of 545 consecutive patients were included in the study. Among all, 182 (33.3%), 183 (33.3%), and 180 (33.3%) patients underwent mitral repair in the control-1, control-2, and NT cohorts, respectively. Procedural success was achieved in 93.3% of patients without differences between groups. Major adverse events did not statistically differ among groups, but there was a higher rate of pericardial effusion in the control-1 group (4.3%, 0.6%, and 2.6%, respectively; p = 0.025). The composite endpoint of death, surgery, and admission for congestive heart failure (CHF) at 12 months was lower in the NT group (23.5% in control-1, 22.5% in control-2, and 8.3% in the NT group; p = 0.032). Conclusions: The present paper shows that contemporary clinical outcomes of patients undergoing PMVR with the Mitraclip system have improved over time.
AB - Background and aim: Recent randomized data comparing percutaneous mitral valve repair (PMVR) versus optimal medical treatment in patients with functional MR (FMR) seemed to highlight the importance of the learning curve not only for procedural outcomes but also for patient selection. The aim of the study was to compare a contemporary series of patients undergoing PMVR using a second-generation Mitraclip device (Mitraclip NT) with previous cohorts treated with a first-generation system. Methods: This multicenter study collected individual data from 18 centers between 2012 and 2017. The cohort was divided into three groups according to the use of the first-generation Mitraclip during the first (control-1) or second half (control-2) or the Mitraclip NT sys-tem. Results: A total of 545 consecutive patients were included in the study. Among all, 182 (33.3%), 183 (33.3%), and 180 (33.3%) patients underwent mitral repair in the control-1, control-2, and NT cohorts, respectively. Procedural success was achieved in 93.3% of patients without differences between groups. Major adverse events did not statistically differ among groups, but there was a higher rate of pericardial effusion in the control-1 group (4.3%, 0.6%, and 2.6%, respectively; p = 0.025). The composite endpoint of death, surgery, and admission for congestive heart failure (CHF) at 12 months was lower in the NT group (23.5% in control-1, 22.5% in control-2, and 8.3% in the NT group; p = 0.032). Conclusions: The present paper shows that contemporary clinical outcomes of patients undergoing PMVR with the Mitraclip system have improved over time.
KW - Transcatheter mitral valve repair
KW - Mitral regurgitation
KW - MitraClip
U2 - 10.3390/jcm10040734
DO - 10.3390/jcm10040734
M3 - Article
C2 - 33673247
SN - 2077-0383
VL - 10
SP - 1
EP - 10
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 4
ER -